{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:36:01Z","timestamp":1787664961171,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The AE records were selected by searching the FDA Adverse Event Reporting System database from the first quarter of 2009 to the first quarter of 2022. Potential adverse event signals were mined using the disproportionality analysis, including reporting odds ratio the proportional reporting ratio the Bayesian confidence propagation neural network and the empirical Bayes geometric mean and MedDRA was used to systematically classify the results.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 24,575 AE reports of Everolimus were obtained using data from the FAERS database, and Everolimus-induced AEs occurrence targeted 24 system organ classes after conforming to the four algorithms simultaneously. The common significant SOCs were identified, included benign, malignant and unspecified neoplasms, reproductive system and breast disorders,\n                    <jats:italic>etc.<\/jats:italic>\n                    The significant AEs were then mapped to preferred terms such as stomatitis, pneumonitis and impaired insulin secretion, which have emerged in the study usually reported in patients with Everolimus. Of note, unexpected significant AEs, including biliary ischaemia, angiofibroma, and tuberous sclerosis complex were uncovered in the label.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study provided novel insights into the monitoring, surveillance, and management of adverse drug reaction associated with Everolimus. The outcome of serious adverse events and the corresponding detection signals, as well as the unexpected significant adverse events signals are worthy of attention in order to improving clinical medication safety during treatment of Everolimus.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1333662","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:28:55Z","timestamp":1710214135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Bin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1756283X16674660","article-title":"Everolimus in the management of metastatic neuroendocrine tumours","volume":"10","author":"Chan","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.breast.2015.09.002","article-title":"Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study","volume":"24","author":"Chocteau-Bouju","year":"2015","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","article-title":"Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome","volume":"48","author":"Dabydeen","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.3892\/mmr.2018.8769","article-title":"Everolimus inhibits breast cancer cell growth through PI3K\/AKT\/mTOR signaling pathway","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1399-0012.2005.00356.x","article-title":"Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients","volume":"19","author":"Garrean","year":"2005","journal-title":"Clin Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clgc.2014.12.011","article-title":"A single-arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma","volume":"13","author":"Kanesvaran","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/cncr.26429","article-title":"Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma","volume":"118","author":"Molina","year":"2012","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14656566.2023.2214677","article-title":"Evaluating everolimus for the treatment of breast cancer","volume":"24","author":"Moreau-Bachelard","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12282-013-0444-8","article-title":"Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2","volume":"21","author":"Noguchi","year":"2014","journal-title":"Breast Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2017.05.004","article-title":"Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma","volume":"81","author":"Penttil\u00e4","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The role of mTOR signaling as a therapeutic target in cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.transproceed.2007.06.030","article-title":"Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients","volume":"39","author":"S\u00e1nchez Fructuoso","year":"2007","journal-title":"Transpl. Proc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/ftd.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/03007995.2018.1558883","article-title":"Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma","volume":"35","author":"Song","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 years","volume":"43","author":"Song","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/oncolo\/oyab024","article-title":"Everolimus-induced pneumonitis in patients with neuroendocrine neoplasms: real-world study on risk factors and outcomes","volume":"27","author":"Taboada","year":"2022","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1499-3872(15)60419-2","article-title":"Everolimus in de novo liver transplant recipients: a systematic review","volume":"14","author":"Tang","year":"2015","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12328-019-00978-8","article-title":"Severe gastrointestinal hemorrhage related to everolimus: a case report","volume":"12","author":"Tsunematsu","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.21037\/atm-20-6488","article-title":"Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC)","volume":"9","author":"Umeda","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"145992","DOI":"10.1016\/j.gene.2021.145992","article-title":"Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma","volume":"809","author":"Yangyun","year":"2022","journal-title":"Gene"},{"key":"B29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s1875-5364(13)60035-7","article-title":"Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance","volume":"11","author":"Zink","year":"2013","journal-title":"Chin. J. Nat. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1333662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:28:58Z","timestamp":1710214138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1333662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1333662"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1333662","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"article-number":"1333662"}}